Conversation Series | Treatments for ED | Dr Tom Silva
The third video from our Conversation Series with Dr Thomas Silva is now live. Dr Silva is a specialist GP and University of Queensland lecturer with unique expertise in erectile dysfunction treatments, including experience with complex post-prostate cancer cases. In this video, Dr Silva provides a comprehensive overview of current ED medications and their mechanisms […]
Key results from the LTP pivotal study – SPONTAN® Nasal Spray works significantly faster
LTR Pharma has today announced key results from its pivotal study demonstrating that SPONTAN® Nasal Spray works significantly faster than the oral tablet, achieving 470% faster absorption than oral vardenafil tablets and reaching its peak concentration in 12 min vs 56 min. SPONTAN also displayed clinically relevant comparable bioavailability, with 111.8% dose-normalised bioavailability relative to […]
The Courier Mail, The Australian | ‘Brisbane drug company gets the rise on Viagra’
News Corp (The Courier Mail, The Australian) Business Journalist, Glen Norris, has published an article in today’s business section titled ‘Brisbane drug company gets the rise on Viagra’. It examines the PDE5 inhibitor market and why SPONTAN® may be a preferred treatment, as a potentially fast-acting intranasal spray solution. Click here to read the full […]
Ausbiz | LTR Pharma ASX Debut
LTR Pharma (ASX:LTP) Independent Non-Executive Director, Dr Julian Chick, was interviewed on Ausbiz to discuss the Company’s ASX debut. Take a look:
Biotech Daily | 11 December 2023
LTR Pharma has again been featured in Biotech Daily in an article titled, ‘LTR Up 105% On Spontan Erectile Dysfunction IPO’. Read the full report.
Stockhead | ‘Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX’
Stockhead journalist, Rob Badman, has reported on the upcoming LTR Pharma IPO today in an article title ‘Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX’. Featuring highlights from a 1:1 interview with Alpine Capital‘s Co-Founder and Head of Institutional Sales, Phil Cawood, the article covers interesting […]
Biotech Daily | 17 Nov 2023
LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its commercialisation plans for intra-nasal product, SPONTAN®. The article also showcases the expertise of the team at LTR Pharma, writing: “The company said its Mr Rodne was the former chief executive […]